Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT03120949||Recruiting||Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 or 3.||
||Industry / Other||
||1880||All||18 Years and older (Adult, Older Adult)||NCT03120949||CL04041024
|CREDO 4||July 4, 2017||July 2021||November 2021||April 19, 2017||June 25, 2018||